PRISMASOL B22GK 2/2.5 IN PLASTIC CONTAINER
Clinical safety rating: caution
Comprehensive clinical and safety monograph for PRISMASOL B22GK 2/2.5 IN PLASTIC CONTAINER (PRISMASOL B22GK 2/2.5 IN PLASTIC CONTAINER).
Prismasol B22GK is a sterile hemodialysis solution containing electrolytes and buffer (lactate or bicarbonate). It corrects electrolyte imbalances, acid-base disturbances, and removes uremic toxins by diffusion and convection across a semipermeable membrane during continuous renal replacement therapy (CRRT).
| Metabolism | Lactate is metabolized to bicarbonate in the liver and other tissues via lactate dehydrogenase; bicarbonate may directly buffer acidosis. |
| Excretion | Renal: 100% (mainly as bicarbonate and other buffer components; not metabolized). Biliary/fecal: negligible. |
| Half-life | Not applicable; continuous infusion with rapid renal elimination. For lactate, endogenous half-life ~5-10 minutes under normal conditions. |
| Protein binding | Negligible; components such as lactate and bicarbonate are not significantly protein-bound. |
| Volume of Distribution | 0.2-0.3 L/kg; corresponds to extracellular fluid volume, reflecting distribution limited to plasma and interstitial space. |
| Bioavailability | By IV route: 100% (not orally administered). |
| Onset of Action | Immediate upon IV administration; clinical effects (e.g., acid-base correction) appear within minutes. |
| Duration of Action | Duration of effect lasts only during continuous infusion; effects reverse rapidly upon discontinuation (within 30-60 minutes). |
Not applicable; PRISMASOL B22GK is a hemodialysis/hemofiltration solution used for continuous renal replacement therapy (CRRT) at flow rates of 1000-3000 mL/h according to patient needs and machine settings.
| Dosage form | INJECTABLE |
| Renal impairment | No dose adjustment required; the product is specifically for renal replacement therapy in acute kidney injury. |
| Liver impairment | No specific adjustment for hepatic impairment; use with caution in severe hepatic failure due to lactic acidosis risk from lactate buffer. |
| Pediatric use | Dosing based on patient weight and CRRT prescription; typical blood flow rates 3-5 mL/kg/min and dialysate/replacement flow rates 1000-2000 mL/h/1.73 m². |
| Geriatric use | No specific dose adjustment; monitor fluid and electrolyte balance closely due to age-related physiological changes. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for PRISMASOL B22GK 2/2.5 IN PLASTIC CONTAINER (PRISMASOL B22GK 2/2.5 IN PLASTIC CONTAINER).
| Breastfeeding | PRISMASOL B22GK is a dialysis solution; systemic absorption negligible. Dialysis typically reduces drug/toxin levels in milk. No M/P ratio available; components are endogenous and safe in lactation. Breastfeeding may be limited by maternal disease and treatment schedule. |
| Teratogenic Risk | No known teratogenic risk; PRISMASOL B22GK is a sterile hemodialysis concentrate containing electrolytes and glucose. Individual components (sodium, potassium, calcium, magnesium, chloride, bicarbonate, glucose) are physiologic and not associated with teratogenicity. However, the underlying renal condition requiring dialysis poses significant fetal risks including prematurity, growth restriction, and preeclampsia. Hemodialysis itself may cause fetal distress due to fluid shifts and maternal hypotension. |
■ FDA Black Box Warning
Not available (no FDA boxed warning; use only under physician supervision for CRRT).
| Serious Effects |
["Hyperkalemia (unless correcting severe hyperkalemia)","Severe metabolic alkalosis","Known hypersensitivity to components","Uncorrected hypocalcemia (if citrate anticoagulation used)"]
| Precautions | ["Monitor serum electrolytes, acid-base status, and fluid balance carefully","Risk of electrolyte disturbances (hyper/hypokalemia, hyper/hyponatremia)","Risk of metabolic alkalosis (especially with bicarbonate-based solutions)","Hypersensitivity reactions possible","Use with caution in liver failure (lactate metabolism impaired)"] |
Loading safety data…
| Fetal Monitoring | Monitor fetal growth (serial ultrasound), amniotic fluid index, fetal heart rate during dialysis for signs of distress. Maternal: serum electrolytes, acid-base status, blood pressure, fluid balance, dialysis adequacy (Kt/V). |
| Fertility Effects | No direct effect on fertility; chronic kidney disease (CKD) requiring dialysis is associated with reduced fertility, anovulation, and menstrual irregularities. Dialysis may improve uremic milieu and potentially enhance fertility compared to untreated CKD. |